Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 | P11926 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221671 | 1.00 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL2127510 | 1.00 | — | — | |
| SCHEMBL24500071 | 1.00 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL16329755 | 1.00 | ODC1 (0.47) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL8470775 | 0.87 | MEN1 (0.55) | ODC1MEN1KMT2A | |
| SCHEMBL11885390 | 0.86 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL19107454 | 0.86 | MEN1 (0.38) | ODC1MEN1KMT2A | |
| SCHEMBL14745208 | 0.86 | MEN1 (0.38) | ODC1MEN1KMT2A | |
| SCHEMBL2639323 | 0.86 | MEN1 (0.38) | ODC1MEN1KMT2A | |
| Aminooxyethoxyethoxyethylhydroxylamine SCHEMBL43069 | 0.86 | ODC1 (0.41) | ODC1ADRB2ADRB1ADRB3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086767-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230323344-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | ARES CAPITAL CORPORATION, AS AGENT | 2023-10-12 | — | — | US | disclosed |
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4101930-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ModernaTX, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| EP-3350333-B1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNATX INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| US-20190078087-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | ARES CAPITAL CORPORATION, AS AGENT | 2019-03-14 | — | — | US | disclosed |
| US-10017460-B2 | Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof | ORGANOLINX CORP. (CA) | 2018-07-10 | — | — | US | disclosed |
| US-10017460-B2 | Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof | ORGANOLINX CORP. (CA) | 2018-07-10 | — | — | US | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20160130216-A1 | COMPOUNDS FOR PROMOTING LIPOSOMAL AND CELLULAR ADHESION AND COMPOSITIONS AND METHODS OF USE THEREOF | ORGANOLINX CORP. (CA) | 2016-05-12 | — | — | US | disclosed |
| US-20160130216-A1 | COMPOUNDS FOR PROMOTING LIPOSOMAL AND CELLULAR ADHESION AND COMPOSITIONS AND METHODS OF USE THEREOF | ORGANOLINX CORP. (CA) | 2016-05-12 | — | — | US | disclosed |
| US-20160130216-A1 | COMPOUNDS FOR PROMOTING LIPOSOMAL AND CELLULAR ADHESION AND COMPOSITIONS AND METHODS OF USE THEREOF | ORGANOLINX CORP. (CA) | 2016-05-12 | — | — | US | disclosed |
| WO-2014197991-A1 | COMPOUNDS FOR PROMOTING LIPOSOMAL AND CELLULAR ADHESION AND COMPOSITIONS AND METHODS OF USE THEREOF | YOUSAF MUHAMMAD (CA) | 2014-12-18 | — | — | WO | disclosed |
| US-20070286783-A1 | METHOD OF DEACIDIZING A GASEOUS EFFLUENT WITH EXTRACTION OF THE PRODUCTS TO BE REGENERATED | CARRETTE PIERRE-LOUIS | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | SNRPE, FUT6, ALG8 | ODC1 2742/4885ADRB2 4796/4885ADRB1 4737/4885 |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UCHL5, UCHL3, UCHL1 | ODC1 3564/4885ADRB2 4416/4885ADRB1 4317/4885 |
| US-10017460-B2 | Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof | LPAR2, SGMS2, PHOSPHO1 | ODC1 3068/4885ADRB2 1689/4885ADRB1 2912/4885 |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | ODC1 3381/4885ADRB2 4830/4885ADRB1 4801/4885 |
| US-20160130216-A1 | COMPOUNDS FOR PROMOTING LIPOSOMAL AND CELLULAR ADHESION AND COMPOSITIONS AND METHODS OF USE THEREOF | LPAR2, SGMS2, PHOSPHO1 | ODC1 3068/4885ADRB2 1689/4885ADRB1 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.